531210 COLINZ

Colinz Laboratories Share Price

₹55.14 +2.62 (4.99%)

24 Nov, 2024 02:03

SIP TrendupStart SIP in COLINZ

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month + 1.36%
  • Over 3 Month + 6.35%
  • Over 6 Month + 34.06%
  • Over 1 Year + 33.03%
SIP Lightning

Smart Investing Starts Here Start SIP with Colinz Laboratories for Steady Growth!

Invest Now

Colinz Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Colinz Laboratories Financials

Colinz Laboratories Technicals

EMA & SMA

Current Price
₹55.14
+ 2.62 (4.99%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹58.91
  • 50 Day
  • ₹58.68
  • 100 Day
  • ₹57.04
  • 200 Day
  • ₹52.96

Resistance and Support

55.01 Pivot Speed
  • R3 55.42
  • R2 55.28
  • R1 55.15
  • S1 54.88
  • S2 54.74
  • S3 54.61

What's your outlook on Colinz Laboratories?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Colinz Laboratories has an operating revenue of Rs. 6.95 Cr. on a trailing 12-month basis. An annual revenue de-growth of 0% needs improvement, Pre-tax margin of 9% is okay, ROE of 5% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 66 which is FAIR indicating the recent price performance, Buyer Demand at C which is evident from recent supply seen, Group Rank of 35 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Colinz Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-30 Quarterly Results
2024-08-08 Others Inter-alia, 1. To Consider and approve the Director's Report for the year ended 31st March, 2024. 2. To Consider and approve the Management Discussion Report, Corporate Governance Report.
2024-07-31 Quarterly Results
2024-05-29 Quarterly Results
2024-01-31 Quarterly Results

Colinz Laboratories F&O

Colinz Laboratories Shareholding Pattern

66%
31.04%
2.96%

About Colinz Laboratories

  • NSE Symbol
  • COLINZ
  • BSE Symbol
  • 531210
  • ISIN
  • INE923C01011

Similar Stocks to Colinz Laboratories

Colinz Laboratories FAQs

Colinz Laboratories share price is ₹55 As on 24 November, 2024 | 01:49

The Market Cap of Colinz Laboratories is ₹13.9 Cr As on 24 November, 2024 | 01:49

The P/E ratio of Colinz Laboratories is 26 As on 24 November, 2024 | 01:49

The PB ratio of Colinz Laboratories is 1.6 As on 24 November, 2024 | 01:49

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23